Progresif Multifokal Lökoensefalopati
Özet
Progresif multifokal lökoensefalopati (PML), genellikle immünsüpresyon varlığında JC virüsünün (JCV) reaktivasyonu sonucu ortaya çıkan, merkezi sinir sistemini etkileyen ölümcül bir hastalıktır. Virüs, beyindeki myelin üreten oligodendrositlerde litik enfeksiyona ve buna bağlı olarak beyaz cevherde multifokal demyelinizasyona yol açar. Klinik tablo, bilişsel gerileme, motor bozukluklar ve nörolojik kayıplarla karakterizedir. Spesifik bir antiviral tedavisi bulunmamakta olup, en etkili strateji immün sistemin yeniden yapılandırılmasıdır.
Progressive multifocal leukoencephalopathy (PML) is a fatal disease of the central nervous system caused by the reactivation of the JC virus (JCV), typically occurring in the presence of immunosuppression. The virus causes lytic infection of oligodendrocytes, leading to multifocal demyelination within the brain's white matter. Clinical presentation is characterized by cognitive decline, motor impairment, and various neurological deficits. There is no specific antiviral treatment, and immune reconstitution remains the most effective strategy for management.
Referanslar
Astrom KE, Mancall EL, Richardson EP Jr. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958; 81:93.
Padgett BL, Walker DL, ZuRhein GM, et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971; 1:1257.
Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9:425.
Weber T, Trebst C, Frye S, et al. Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis 1997; 176:250.
Kartau M, Sipilä JO, Auvinen E, et al. Progressive Multifocal Leukoencephalopathy: Current Insights. Degener Neurol Neuromuscul Dis 2019; 9:109.
Moll NM, Rietsch AM, Ransohoff AJ, et al. Cortical demyelination in PML and MS: Similarities and differences. Neurology 2008; 70:336.
Wüthrich C, Koralnik IJ. Frequent infection of cortical neurons by JC virus in patients with progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 2012; 71:54.
Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name? Ann Neurol 2006; 60:162.
García-Suárez J, de Miguel D, Krsnik I, et al. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 2005; 80:271.
Gonzalez H, Bolgert F, Camporo P, Leblond V. Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP). Hematol Cell Ther 1999; 41:183.
Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013; 80:1430.
Aksamit AJ Jr. Progressive multifocal leukoencephalopathy. Continuum (Minneap Minn) 2012; 18:1374.
Berger JR, Scott G, Albrecht J, et al. Progressive multifocal leukoencephalopathy in HIV-1-infected children. AIDS 1992; 6:837.
Dankner WM, Lindsey JC, Levin MJ, Pediatric AIDS Clinical Trials Group Protocol Teams 051, 128, 138, 144, 152, 179, 190, 220, 240, 245, 254, 300 and 327. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J 2001; 20:40.
Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002; 8 Suppl 2:115.
Mateen FJ, Muralidharan R, Carone M, et al. Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol 2011; 70:305.
Govinathan Vivekanandan, Ansha P Abubacker, Revathi Myneni, Harsh V Chawla, Aimen Iqbal, Amit Grewal, Andrew Ndakotsu, Safeera Khan. Risk of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patient Treated With Natalizumab: A Systematic Review. Cureus. 2021 Apr; 13(4): e14764
Koralnik IJ. Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis. Erişim:www.uptodate.com
Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum 2010; 62:3191.
Iacobaeus E, Burkill S, Bahmanyar S, et al. The national incidence of PML in Sweden, 1988-2013. Neurology 2018; 90:e498.
Sipilä JOT, Soilu-Hänninen M, Rautava P, Kytö V. Progressive multifocal leukoencephalopathy in Finland: a cross-sectional registry study. J Neurol 2019; 266:515.
Haider S, Nafziger D, Gutierrez JA, et al. Progressive multifocal leukoencephalopathy and idiopathic CD4+lymphocytopenia: a case report and review of reported cases. Clin Infect Dis 2000; 31:E20.
McGuire JL, Fridman V, Wüthrich C, et al. Progressive multifocal leukoencephalopathy associated with isolated CD8+ T-lymphocyte deficiency mimicking tumefactive MS. J Neurovirol 2011; 17:500.
Zerbe CS, Marciano BE, Katial RK, et al. Progressive Multifocal Leukoencephalopathy in Primary Immune Deficiencies: Stat1 Gain of Function and Review of the Literature. Clin Infect Dis 2016; 62:986.
PML diagnostic criteria. Consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013; 80(15): 1430–1438.
Bernal-Cano F, Joseph JT, Koralnik IJ. Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient. J Neurovirol 2007;13: 474–476.
Wuthrich C, Dang X, Westmoreland S, et al. Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol 2009;65:742–748.
Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011; 77:1061.
Gheuens S, Smith DR, Wang X, et al. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology 2012; 78:1390.
Du Pasquier RA, Corey S, Margolin DH, et al. Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual. Neurology 2003; 61:775.
Agnihotri SP, Wuthrich C, Dang X, et al. A fatal case of JC virus meningitis presenting with hydrocephalus in a human immunodeficiency virus-seronegative patient. Ann Neurol 2014; 76:140.
Whiteman ML, Post MJ, Berger JR, Tate LG, Bell MD,Limonte LP. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology 1993;187:233–240.
Yousry TA, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2012;72:779–787.
Brochet B, Dousset V. Pathological correlates of magnetization transfer imaging abnormalities in animal models and humans with multiple sclerosis.Neurology1999;53:S12–S17.
Whiteman ML, Post MJ, Berger JR, et al. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology 1993; 187:233.
Skiest DJ. Focal neurological disease in patients with acquired immunodeficiency syndrome. Clin Infect Dis 2002; 34:103.
Kuhle J, Gosert R, Buhler R, et al. Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated MS patient. Neurology 2011;77: 2010–2016.
Markowitz RB, Thompson HC, Mueller JF, Cohen JA, Dynan WS. Incidence of BK virus and JC virus viruria in human immunodefi ciency virus-infected and -uninfected subjects. J Infect Dis 1993; 167: 13–20.
Koralnik IJ, Boden D, Mai VX, Lord CI, Letvin NL. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 1999; 52: 253–60.
Cinque P, Koralnik IJ, Clifford DB. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol 2003;9(suppl 1):88–92.
Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Irene Cortese, Daniel S. Reich, Avindra Nath. Nat Rev Neurol. 2020 Nov 20 : 1–15.
Hall CD, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N. Engl. J. Med. 1998;338:1345–1351.
Royal W, et al. Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. J. Neurovirol. 2003;9:411–419.
De Luca A, et al. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS. 2008;22:1759–1767.
Clifford DB, et al. A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J. Neurovirol. 2013;19:351–358
Landi D, et al. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology. 2017;88:1144–1152.
Kunschner L, Scott TF. Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2. Neurology. 2005;65:1510–1510.
Stefoski D, et al. Treatment of natalizumab-associated PML with filgrastim. Ann. Clin. Transl. Neurol. 2019;6:923–931.
Gasnault J., et al. Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy. Open Forum Infect. Dis.10.1093/ofid/ofu074 (2014)
Balduzzi A, et al. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transpl. 2011;46:987–992.
